Article abstract-We reviewed the correlation between malignant cells in cerebrospinal fluid (CSF) (positive cytology) and pathologic findings at autopsy. The purpose was to discover: (1) the incidence of negative CSF cytology in patients with CNS malignancy, (2) the incidence of false-positive cytology, and (3) the relationship between a true-positive cytology and the distribution of malignant tumor a t autopsy. Of 117 patients with CNS tumor and premortem cytologic examination of the CSF, 3 1 (26 percent) were positive and 86 (74 percent) were negative. Only 1 of 66 patients with tumor that did not reach the leptomeninges had a positive cytology. Of 51 patients with leptomeningeal tumor at autopsy, cytology was positive in 30 (59 percent) and negative in 21 (41 percent). Five potentially "false-positive" cytologies were encountered: Three patients were treated, and tumor may have been eradicated; in two patients with lymphoma, inflammatory cells associated with infection were apparently mistaken for malignant cells. These data indicate that a positive CSF cytology is a reliable indicator of CNS malignancy and almost always reflects leptomeningeal tumor.
patients harboring malignant tumors of the CNS. Most of these reports dealt with only small numbers of metastatic tumors and did not address three major clinical considerations: (1) the incidence of negative CSF cytology in patients with histologically proved brain or, especially, leptomeningeal tumors, (2) the incidence of falsepositive cytology, and (3) the relationship between positive cytology and distribution of the tumor at autopsy. Since all of these clinical considerations have therapeutic implications, we reviewed our experience with cytologic examination of the CSF in patients subsequently examined at autopsy. Because of the nature of Memorial Sloan-Kettering Cancer Center's (MSKCC) hospital population, this report deals largely with CNS metastases rather than with primary brain tumors.
Materials and methods. The records of the
Cytology Laboratory and the Autopsy Service of MSKCC for the years 1976 and 1977 were compared. We identified all patients who had cytologic examination of the CSF prior to death, whether positive or negative, and who subsequently underwent autopsy that included the CNS. The pathologic examination of the nervous system was performed by one neuropathologist (N.L.C.) using a standardized coding system12 that emphasizes the extent and distribution of disease. Because of our interest in leptomeningeal metastases, special attempts were made to identify this neurologic complication of systemic cancer. 13 Patients harboring CNS neoplasms were classified into three groups: (1) those with dural metastases, including invasion of the cavernous space, other dural sinuses or the subdural surface of brain or spinal cord; (2) those with parenchymal tumors within the substance of the brain or spinal cord; and (3)
Results. Autopsy findings. During 1976 and 1977 there were 777 autopsies of patients who died with malignant neoplasms and whose brains and spinal cords were examined; 363 of these patients were considered to be "neuropathology cases," requiring more careful examination because the patient had been evaluated neurologically during life or because a suspicious CNS lesion was encountered by the prosector on gross or microscopic examination. In 210 patients, tumor was found in CNS (table 1) .
One hundred forty-two patients had malignant tumors within the parenchyma of the brain or spinal cord. In 98 of these patients, there was no evidence of leptomeningeal or dural involvement; in the other 44 there was additional tumor in the leptomeninges as well as the brain or spinal cord. These 142 parenchymal lesions include 114 metastatic lesions and 28 primary CNS tumors (table  1) .
Fifty patients had dural lesions. All were metastatic; 33 had no additional leptomeningeal involvement, and in 17 leptomeningeal metastases accompanied the dural involvement. Seventythree patients had histologic evidence of leptomeningeal tumor, either metastases from a systemic cancer or direct spread from a primary brain between the last antemortem CSF examination and death varied, but in most patients it was less than 30 days. Of the 117 patients with CNS tumor and premortem cytologic examination of the CSF, 31 (26 percent) were positive at least once and 86 (74 percent) were negative. The CSF cytology was negative in all except 1 of the 66 patients with parenchymal or dural lesions without leptomeningeal involvement. Of the 22 patients with both parenchymal disease and leptomeningeal disease, there were 12 positive cytologies and 10 negative cytologies. In the eight patients with leptomeningeal involvement in addition to dural tumor, there were five positive and three negative cytologies. Thus, in only one instance were malignant cells found in the CSF of patients whose meninges were not invaded by tumor at autopsy, and that patient's cytology reverted to negative with treatment, which may have eradicated previously present leptomeningeal disease. The CSF was examined before death in 51 of the 73 patients with autopsy-proved leptomeningeal tumor. These include metastases from a variety of primary tumors (table 3); in 30 patients (59 percent), the cytology was positive and in 21 it was negative. No primary tumor appeared to exude cells into the CSF more consistently than any other. The incidence of positive cytologies correlated with the extent of disease (table 4). Of the 73 patients with leptomeningeal metastases, the disease was focal in 19 and multifocal or disseminated in 54. Among the 13 patients with focal leptomeningeal seeding and CSF examination, 5 cytologies were positive (38 percent) and 8 negative. Of the 38 patients with disseminated leptomeningeal tumor and CSF examination, 25 were positive (66 percent) and 13 negative ( figure 4) . When viewed the other way, 25 of 30 patients with a positive CSF cytology had disseminated leptomeningeal disease (83 percent); only 5 of the 30 positive CSFs occurred with focal involvement. In 13 of the 21 patients with a negative CSF cytology the leptomeningeal disease was disseminated, and in 8 it was focal.
'?False-positive cytology." Five patients with malignant cells in CSF had no evidence of CNS malignancy a t autopsy. These included three patients with lymphoma, one with acute myelocytic leukemia, and one with medulloblastoma (table 5). The patients with medulloblastoma and acute myelocytic leukemia both had clinical evidence of leptomeningeal involvement during life, and both were treated for that disorder. Both responded to treatment clinically, and malignant cells disappeared from the CSF before death. Thus, the disease was probably eradicated from the CNS in these patients prior to death, and they were not really false-positives. The same may have been true for one patient with lymphoma (patient 3) who received radiation therapy to the brain to treat multiple cranial nerve dysfunction. Cytology was positive prior to radiation therapy, and there was no follow-up CSF cytology. Patient 1 received intrathecal chemotherapy as prophylaxis against meningeal metastasis in September and October 1975. In November 1976, CSF cytology was read as positive, but there was no clinical evidence of either leptomeningeal tumor or meningitis. CSF cultures for bacteria and fungi were negative, and all other CSF measurements were normal. There was no known cause for the positive cytology. Patient 2 was also a true false-positive. Apparently malignant cells appeared in the CSF in association with disseminated herpes zoster and symptoms of herpes zoster meningitis. No therapy was given to the CNS for malignant lymphoma, and when the generalized zoster cleared the CSF cytology became negative.
Discussion. We undertook this retrospective analysis of cytologic examinations of the CSF for three reasons: (1) It had been our clinical impression that positive cytology was strong evidence that a malignant brain tumor had not only reached the ventricular or leptomeningeal surface but had seeded the leptomeninges, at least in focal areas. Although it had been recognized that tumor cells could not appear in the CSF unless they reached the leptomeningeal or ventricular s u~f a c e ,~*~,~* few attempts had been made to correlate the findings in the CSF with the presence and extent of leptomeningeal seeding at autopsy, and it has been implied that parenchymal lesions can and do exude malignant cells into the CSF. Since we consider malignant cells in the CSF as presumptive evidence of meningeal seeding, and treat patients on that basis, this is of clinical importance. (2) We were also concerned about the possibility of falsepositive cytologic diagnoses. In recent years we 
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have encountered an increasing number of positive cytologic diagnoses, and we occasionally considered some to be falsely positive. This survey appears to answer all three questions. At least in our hands, malignant cells in the CSF imply that the leptomeninges have been seeded by viable tumor. Moreover, tumor is usually not just present in a focal area of leptomeninges, but has seeded the leptomeninges rather widely in a multifocal or disseminated fashion. This statement applies not only to metastatic CNS neoplasms but also to primary tumors. Second, false-positive cytologic diagnoses appear to be rare, at least in our experience, and occurred only in patients with lymphoma who were suffering from meningitis in which reactive or immature lymphocytes were mistaken for malignant lymphoid cells. With experience, even most of these cases could be correctly recognized. Thus, in one report of a false-positive cytologic diagnosis,15 lymphocytes from the CSF of a patient suffering from cryptococcal meningitis were interpreted as lymphoma; we believe from the photomicrographs in that article that the cells can be identified as reactive.
False-negative CSF cytology in patients with Our findings differ from other surveys which suggested that parenchymal metastases without leptomeningeal involvement can be identified by examination of CSF. There are several possible reasons for this discrepancy: (1) Our techniques may be less sensitive than other^,^.^^ resulting in excessive false-negative cytologies unless the leptomeninges are widely seeded and large numbers of cells are actually present in the CSF. (2) Previous reports of positive cytologies in parenchymal tumors may not have examined the entire nervous system carefully enough to identify leptomeningeal spread of tumor, which was, in fact, responsible for the positive cytology. (3) We may be "underreading" malignant cells or others may be overreading malignant cells in the CSF. We believe that leptomeningeal metastases may be overlooked a t autopsy if not specifically sought by meticulous examination of the entire CNS in patients with positive cytologies, a practice we have consistently followed. Overall, about 25 percent of our patients with autopsy-proved CNS involvement by malignant tumor had a positive cytology, a figure similar to that encountered in most other large series. Furthermore, when considered by individual tumor type, the percentage of cases with positive cytology seen by us was similar to that of other studies. Thus, the difference between our studies and others is not in the technique of isolating and identifying malignant cells in the CSF, but in the meticulous examination of the CNS at autopsy, revealing a much higher incidence of leptomeningeal seeding than was previously apparent.
Conclusions.
We draw several conclusions from these data and our review of the literature: (1) Malignant cells in the CSF mean that there is malignant tumor in the CNS. In rare instances of patients with systemic lymphoma and CNS infection, immature or reactive lymphocytes in the CSF may mimic lymphoma and lead to errors in diagnosis. Occasional patients with systemic leukemia in blastic crisis may seed a few malignant cells into the CSF, but the implications of that are not entirely clear. (2) Malignant cells appear in the CSF most commonly when the leptomeninges are widely seeded by tumor, less often when they are focally seeded by tumor, and almost never when tumor is limited to the brain and the pial surface has not been breached. The clinical implication of this finding is that if malignant cells are present in the CSF, cure by ablative surgery is highly unlikely, and treatment must be directed to the entire neuraxis. (3) Failure to find malignant cells in the CSF does not exclude the diagnosis of leptomeningeal seeding when clinically suspected. An exception is acute lymphoblastic leukemia, which will almost always yield cells in the CSF if the meninges are seeded. (4) Cytologic examination of the CSF may be useful in assessing the results of therapy. Three of our patients with unequivocal clinical evidence of leptomeningeal seeding and positive CSF cytology reverted to negative during the course of treatment, and no tumor was found in their CNS at autopsy.
